Try our beta test site
165 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Rank Status Study
1 Available Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome
Conditions: Congenital Myasthenic Syndrome;   Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4-Diaminopyridine
2 Available Expanded Access to RXDX-105 for Cancers With RET Alterations
Condition: Cancers With RET Alterations
Intervention: Drug: RXDX-105
3 Available Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
Condition: Ewing Sarcoma
Intervention: Drug: Ganitumab
4 Available Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: Niraparib
5 Available Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion
Conditions: Cancer;   Neurotrophic Tyrosine Kinase, Receptor-related Proteins
Intervention: Drug: larotrectinib
6 Available Dupilumab Compassionate Use Study
Condition: Asthma
Intervention: Drug: Dupilumab
7 Available Study of Cannabidiol for Drug-Resistant Epilepsies
Condition: Drug Resistant Epilepsy
Intervention: Drug: Cannabidiol
8 Available An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC
Conditions: Malignant Neoplasms of Digestive Organs;   Neuroendocrine Tumor;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
Interventions: Drug: 68Ga-DOTATOC;   Procedure: PET/CT
9 Available Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation;   Triple-Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Cisplatin;   Drug: Vinorelbine
10 Available Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Condition: Heart Decompensation
Intervention: Drug: Levosimendan
11 Available A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease
Condition: CLN2 Disease
Intervention: Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)
12 Available Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Ultratrace Iobenguane I131
13 Available Therasphere for Unresectable Primary or Secondary Liver Neoplasia
Conditions: Liver Cancer;   Liver Neoplasms;   HepatoCellular Carcinoma
Intervention: Device: TheraSphere Treatment
14 Available Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
Conditions: Neoplasm;   Desmoid Tumor
Intervention: Drug: PF-03084014
15 Available Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Conditions: TTR-mediated Amyloidosis;   Amyloidosis, Hereditary;   Amyloid Neuropathies, Familial;   Familial Amyloid Polyneuropathies;   Amyloid Neuropathies;   Amyloidosis, Hereditary, Transthyretin-Related
Intervention: Drug: patisiran (ALN-TTR02)
16 Available The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules
Condition: Thyroid Nodules
Intervention: Device: SWE
17 Available Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
Condition: Total Parenteral Nutrition-induced Cholestasis
Intervention: Drug: Omegaven IV lipid emulsion
18 Available Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children
Condition: Parenteral Nutrition-Associated Liver Disease
Intervention: Drug: Omegaven
19 Available cliniMACs HUD for T Cell Depletion
Condition: x Linked Combined Immunodeficiency
Intervention: Device: CliniMACs
20 Available Rivaroxaban in Mechanical Valves: RIMV Study
Condition: Thromboembolism
Intervention: Drug: Rivaroxaban

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.